Global Blood Transfusion Diagnostics Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Blood Transfusion Diagnostics Market Research Report 2024
Intravenous transfer of blood or blood products is known as blood transfusion. Replacement of lost blood components can be done with the help of blood transfusion. Blood components like red blood cells, white blood cells, platelets, clotting factors and plasma are mostly transfused. These blood components are of great importance to laboratories and hospitals during an emergency or a critical case of large volume of blood loss. RBC transfusion is done when hemoglobin levels fall below 100g/L. Blood collected from the donor has to be screened for a number of infectious disease before transfusion. Thus, blood transfusion diagnostics play an important role in blood transfusion in order to avoid infection to both the receiver and healthcare staff.
According to MRAResearch’s new survey, global Blood Transfusion Diagnostics market is projected to reach US$ 4338.7 million in 2033, increasing from US$ 3034.7 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Blood Transfusion Diagnostics market research.
Key companies engaged in the Blood Transfusion Diagnostics industry include Grifols, Thermo Fisher Scientific, Roche, bioMérieux, Bio-Rad, Ortho Clinical Diagnostics, Becton Dickinson, Fujirebio and DiaSorin(American Standard Companies), etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Blood Transfusion Diagnostics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Blood Transfusion Diagnostics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Blood Transfusion Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Grifols
Thermo Fisher Scientific
Roche
bioMérieux
Bio-Rad
Ortho Clinical Diagnostics
Becton Dickinson
Fujirebio
DiaSorin(American Standard Companies)
Beckman Coulter
Diagast
Abbott
BAG Health Care
Quidel
Segment by Type
ELISA
NAT
Western Blot Assays
Fluorescence Assay
Other Technology
Hospitals
Clinics
Blood Banks
Laboratories
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Blood Transfusion Diagnostics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Blood Transfusion Diagnostics market is projected to reach US$ 4338.7 million in 2033, increasing from US$ 3034.7 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Blood Transfusion Diagnostics market research.
Key companies engaged in the Blood Transfusion Diagnostics industry include Grifols, Thermo Fisher Scientific, Roche, bioMérieux, Bio-Rad, Ortho Clinical Diagnostics, Becton Dickinson, Fujirebio and DiaSorin(American Standard Companies), etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Blood Transfusion Diagnostics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Blood Transfusion Diagnostics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Blood Transfusion Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Grifols
Thermo Fisher Scientific
Roche
bioMérieux
Bio-Rad
Ortho Clinical Diagnostics
Becton Dickinson
Fujirebio
DiaSorin(American Standard Companies)
Beckman Coulter
Diagast
Abbott
BAG Health Care
Quidel
Segment by Type
ELISA
NAT
Western Blot Assays
Fluorescence Assay
Other Technology
Segment by Application
Hospitals
Clinics
Blood Banks
Laboratories
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Blood Transfusion Diagnostics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source